Yonge Street Media, a weekly online magazine that covers talent, innovation, diversity and quality of life stories in the Toronto region, covered Bedside Clinical Systems’ (BCS) launch in their Innovation section on Wednesday, November 7, 2012.
BCS is a MaRS Innovation spin-off company created to commercialize decision-support research emerging from The Hospital for Sick Children (SickKids).
Each year, 5,000 children in North American hospitals experience code-blue incidents; a code blue is an event where patients require immediate resuscitation. One quarter of these incidents result in death,…
ScarX Therapeutics, a spin-off company created by MaRS Innovation and The Hospital for Sick Children (SickKids), was profiled by Business Without Borders on September 25, 2012.
Sean Fine‘s article examines the strategic funding partnership MI pursued with NovoTek Therapeutics Inc. (NovoTek) in China to develop the anti-scarring cream, which was discovered by researchers at SickKids.
A multibillion-dollar market may await ScarX, a Toronto biomedical start-up, but first it had to figure out how to finance the development of its unique cream that reduces scarring after surgery.
Its answer to the shortage of Canadian venture capital in life sciences turned out to be a partnership with a drug company in China.
OtoSim Inc., a MaRS Innovation spin-off company, made its debut on Business News Network’s The Pitchon June 1, 2012.
Louis Hui, OtoSim’s business development manager, had 90 seconds to pitch OtoSim™ — an integrated educational system that dynamically and interactively teaches how to accurately diagnose ear diseases — to The Pitch’s panel of financiers and experts.
OtoSim Inc., a MaRS Innovation spin-off company, is taping an appearance on Business News Network’s The Pitch on May 22, 2012.
Louis Hui, OtoSim’s business development manager, will have 90 seconds to pitch OtoSim™ — an integrated educational system that dynamically and interactively teaches how to accurately diagnose ear diseases — to The Pitch’s panel of financiers and experts.
MaRS Innovation’s ScarX Therapeutics, a strategic partnership with The Hospital for Sick Children (SickKids) and NovoTek Therapeutics Inc. (NovoTek), was featured on the front page of the Globe and Mail on May 7, 2010.
Read the article on Globe and Mail.com (note that depending on when you’re accessing this page, the Globe‘s content may be subject to a pay wall).
MaRS Innovation (MI), The Hospital for Sick Children (SickKids) and NovoTek Therapeutics Inc. (NovoTek) have announced a strategic partnership to co‐develop, and bring to the Chinese market, a novel therapeutic cream aimed at reducing scar formation post surgery.
This project was covered in The Globe and Mail on May 7, 2012.
MaRS Innovation provided crucial commercialization funding to support research from The Hospital for Sick Children MaRS Innovation (MI) and The Hospital for Sick Children (SickKids) have launched OtoSim Inc. to…
Schwartz Reisman Innovation Campus, West Tower
108 College Street, Suite 530
Toronto, ON M5G 0C6
info@tiap.ca